Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.